Biocon Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Liraglutide is indicated for the treatment of insufficiently controlled type 2 diabetes mellitus in adults, adolescents, and children aged 10 years and above and is used as an adjunct to diet and exercise.

The approval follows the US FDA?s earlier clearance for Liraglutide injection (gSaxenda) that the company received on February 24, 2026. Biocon said the latest approval adds to its portfolio of vertically integrated, complex drug products.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25.

Shares of Biocon rose 0.29% to Rs 393.85 on the BSE.

Powered by Capital Market - Live News

Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 394.6, up 0.99% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 25504.3. The Sensex is at 82333.07, up 0.13%. Biocon Ltd has gained around 8.04% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 5.55% in last one month and is currently quoting at 22632.05, up 1.62% on the day. The volume in the stock stood at 19.62 lakh shares today, compared to the daily average of 31.82 lakh shares in last one month.

The benchmark March futures contract for the stock is quoting at Rs 397.7, up 1.21% on the day. Biocon Ltd is up 26.54% in last one year as compared to a 13.13% jump in NIFTY and a 13.84% jump in the Nifty Pharma index.

The PE of the stock is 325.29 based on TTM earnings ending December 25.

Powered by Capital Market - Live News

Biocon has received approval from the U.S. FDA, for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda?).

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity.

GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption.

Powered by Capital Market - Live News

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity.

GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption.

According to IQVIA MAT December 2025 the total addressable market opportunity for GLP-1 in weight loss in the U.S. was US $127 million.

Siddharth Mittal, chief executive officer and managing director, Biocon, said: ?This timely approval of gSaxenda in the United States marks a defining milestone for Biocon, validating our scientific depth, our vertically integrated development and manufacturing platform, and our ability to bring complex drug products to markets around the world.

GLP-1 therapies represent a significant growth driver for the company, with the U.S. being an important market in this strategy.?

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25.

The scrip rose 0.35% to currently trade at Rs 391.70 on the BSE.

Powered by Capital Market - Live News